A phase 1 clinical trial published in 2026 evaluated BBM-P002, an investigational gene therapy for Parkinson disease. Which ...
A target trial emulation pooling ACCORD-BP and SPRINT data found calcium channel blocker regimens reduced blood pressure variability without changing cardiovascular outcomes.
Phase 3 data show the oral BTK inhibitor reduced annualized relapse rate by 35.2% and 31.2% vs teriflunomide, with no liver safety signal or Hy's Law cases. A phase 2 trial found liposomal ...
Remibrutinib (Novartis), an oral Bruton tyrosine kinase (BTK) inhibitor, reduced annualized relapse rate (ARR) vs ...
A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral ...
A professor at Polytechnique Montreal discussed advances in brain and spinal cord MRI for multiple sclerosis, including ...
This week on NeurologyLive, there are a number of hot topics that we will be post ...
Open-label extension data showed that disability trends observed with vidofludimus calcium during the double-blind period of the phase 2 CALLIPER trial persisted with continued treatment in ...
The FDA has accepted the resubmitted new drug application (NDA) for troriluzole (Vyglxia; Biohaven) for the treatment of ...
One-year data from the phase 3 AQUARELLE study show that divozilimab (Biocad), an anti-CD20 monoclonal antibody, reduced ...
This episode, titled ‘Understanding MG Pathophysiology and Therapeutic Targets,’ features panelists examining how advances in ...
FcRn inhibition targets the persistence of pathogenic IgG rather than its production. The panel explains why this downstream ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results